TPP raises £9.6 million for early drug development in Scotland
This article was originally published in Scrip
In a move that will boost Scotland's growing reputation as a base for life sciences research, the UK-based drug development company, TPP Global Development, has decided to set up its new headquarters in the Edinburgh BioQuarter. It has also raised £9.6 million for use in developing early-stage preclinical drug candidates.
You may also be interested in...
As fears grow that a full-blown COVID-19 pandemic may be on the way, a European public-private consortium is to make available a total of €45m (US$49m) in funding for projects aimed at accelerating the development of diagnostics and therapeutics to help tackle the current outbreak and any future coronavirus threats.
Europe’s Innovative Medicines Initiative is calling for R&D projects aimed at tackling the spread of COVID-19, saying that collaborative ventures have the potential to accelerate the development of therapeutics and diagnostics to tackle this and future coronavirus outbreaks.
Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.